Book a Meeting

Non-Fucosylated Anti-Human CD40 (SEA-CD40 (Derived from S2C6)) Therapeutic Antibody (CAT#: BioBet-1665ZP) Datasheet

Target
CD40
Isotype
IgG1
Description
Non-Fucosylated Anti-Human CD40 (SEA-CD40 (Derived from S2C6)) is a glycosylation-modified therapeutic biobetter antibody.
Indication
Lymphoma, B cell
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD40 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD40
Full Name
CD40 Molecule
Background
CD40 (CD40 Molecule) is a Protein Coding gene.
Diseases associated with CD40 include Immunodeficiency With Hyper-Igm, Type 3 and Cd40 Ligand Deficiency.
Among its related pathways are NLR Proteins and Cytokine Signaling in Immune system.
Gene Ontology (GO) annotations related to this gene include enzyme binding and receptor activity.
An important paralog of this gene is TNFRSF11A.
Alternative Names
Tumor necrosis factor receptor superfamily member 5; TNFRSF5; p50
Gene ID
958
UniProt ID
P25942
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
SEA-CD40 (Derived from S2C6)
Host
Humanized
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Indication
Lymphoma, B cell
Synonyms
S2C6; hS2C6

Related Products

Highly Galactosylated Anti-CD40 (Lucatumumab) Antibody (CAT#: BioBet-GA-149ZP)
Highly Galactosylated Anti-CD40 (Selicrelumab) Antibody (CAT#: BioBet-GA-148ZP)
Non-fucosylated Anti-Human CD40 (Teneliximab) Therapeutic Antibody (CAT#: BioBet-147ZP)
Non-Fucosylated Anti-Human CD40 (SEA-CD40) Therapeutic Antibody (CAT#: BioBet-1833ZP)
Non-fucosylated Anti-Human CD40 (Dacetuzumab) Therapeutic Antibody (CAT#: BioBet-146ZP)
Non-fucosylated Anti-Human CD40 (Selicrelumab) Therapeutic Antibody (CAT#: BioBet-148ZP)
Non-fucosylated Anti-Human CD40 (Lucatumumab) Therapeutic Antibody (CAT#: BioBet-149ZP)
BetterBet™ Anti-CD40 Half-Life Extended Antibody (CAT#: AES-0622-ZP1031)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany